<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00399932</url>
  </required_header>
  <id_info>
    <org_study_id>ELASTO1</org_study_id>
    <nct_id>NCT00399932</nct_id>
  </id_info>
  <brief_title>Non-invasive Evaluation of Hepatic Fibrosis in Patients With the Metabolic Syndrome</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) is now recognised as the hepatic complication of&#xD;
      the metabolic syndrome of insulin resistance. In some patients, the disease can progress into&#xD;
      steatohepatitis (NASH) which associates fatty liver, hepatocellular damage, chronic&#xD;
      inflammation and variable and progressive fibrosis. The latter can evolve into cirrhosis and&#xD;
      end-stage liver disease.&#xD;
&#xD;
      Thus the presence of fibrosis sign the severity of the disease, and therefore its accurate&#xD;
      detection is crucial for the identification of patients in need of treatment and appropriate&#xD;
      follow-up.&#xD;
&#xD;
      To date, histological examination of a biopsy of the liver is the gold standard in the&#xD;
      diagnosis of fibrosis. the procedure is however associated with significant complication in&#xD;
      0.01 to 0.1% of cases and with sampling errors because it analyses only a minimal portion fo&#xD;
      the liver.&#xD;
&#xD;
      The aim of the study is to evaluate, in a population of patients with the metabolic syndrome,&#xD;
      whether non-invasive tests may identify those with hepatic fibrosis.&#xD;
&#xD;
      At inclusion, serum tests, fibroscan (elastography of the liver by ultra-sounds) and&#xD;
      elastography by MRI will be performed. Those tests will be repeated within 2 months.&#xD;
&#xD;
      A liver biopsy will be performed if 2 out of the 3 (serum test, fibroscan or elastography)&#xD;
      tests are suggestive of hepatic fibrosis.&#xD;
&#xD;
      This study will allow to determine&#xD;
&#xD;
        -  whether hepatic fibrosis may be detected by non-invasive means in patients with&#xD;
           NAFLD/NASH.&#xD;
&#xD;
        -  whether there is a correlation between non-invase tests and liver biopsy for assessment&#xD;
           of fibrosis and it severity&#xD;
&#xD;
        -  whether the presence of fatty liver interfere with the results of the fibroscan and the&#xD;
           elastography.&#xD;
&#xD;
        -  whether there are metabolic factors associated with an increased risk of fibrosis in&#xD;
           this population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Metabolic Syndrome</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      liver biopsy serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with type 2 diabetes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  metabolic syndrome with 3 out of 5 criteria (ATP III definition)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  alcohol intake &gt; 20g/day (women), &gt; 30g/day (men)&#xD;
&#xD;
          -  chronic liver disease of other cause: viral hepatitis (HBV, HCV), Wilson's disease,&#xD;
             haemochromatosis, alpha1 anti-trypsin deficiency, drug-induced, ...&#xD;
&#xD;
          -  decompensated cirrhosis (Child-Pugh 3)&#xD;
&#xD;
          -  body weight &gt; 120 Kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves J Horsmans, M.D.,PhD</last_name>
    <role>Study Director</role>
    <affiliation>StLuc university hospital, Université catholique de Louvain (UCL), Brussels, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yves J Horsmans, M.D.,Ph.D.</last_name>
    <phone>32 2 764 28 37</phone>
    <email>horsmans@gaen.ucl.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bernard VanBeers, M.D.</last_name>
    <phone>32 2 764 29 45</phone>
    <email>vanbeers@rdgn.ucl.ac.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>StLuc University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michel Hermans, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>November 14, 2006</study_first_submitted>
  <study_first_submitted_qc>November 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2006</study_first_posted>
  <last_update_submitted>September 17, 2009</last_update_submitted>
  <last_update_submitted_qc>September 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof Y Horsmans</name_title>
    <organization>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</organization>
  </responsible_party>
  <keyword>metabolic syndrome</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>NASH</keyword>
  <keyword>hepatic fibrosis</keyword>
  <keyword>Fibroscan</keyword>
  <keyword>elastography by MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

